neupro rotigotine 2 mg/24 hr transdermal patch sachet
ucb australia pty ltd t/a ucb pharma division of ucb australia - rotigotine, quantity: 4.5 mg - drug delivery system, transdermal - excipient ingredients: dl-alpha-tocopherol; ascorbyl palmitate; povidone; sodium metabisulfite; methylated trimethylated silica; heptane - parkinson's disease: neupro is indicated as monotherapy, or in combination with levodopa, for the treatment of idiopathic parkinson's disease from early stage to advanced disease. restless legs syndrome: neupro is indicated for the symptomatic treatment of moderate to severe idiopathic restless legs syndrome in adults.
norspan buprenorphine 20microgram/hour transdermal drug delivery system sachet
mundipharma pty ltd - buprenorphine, quantity: 20 mg - drug delivery system, transdermal - excipient ingredients: oleyl oleate; povidone; levulinic acid; polyethylene terephthalate; ethyl acetate; 2-ethylhexyl acrylate; vinyl acetate; butyl acrylate; acrylic acid; 2,2'-azobisisobutyronitrile; aluminium acetylacetonate; heptane - norspan patches are indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. norspan patches are not indicated for use in chronic non-cancer pain other than in exceptional circumstances. norspan patches are not indicated as an as-needed (prn) analgesia.
norspan buprenorphine 10microgram/hour transdermal drug delivery system sachet
mundipharma pty ltd - buprenorphine, quantity: 10 mg - drug delivery system, transdermal - excipient ingredients: oleyl oleate; povidone; levulinic acid; polyethylene terephthalate; ethyl acetate; 2-ethylhexyl acrylate; vinyl acetate; butyl acrylate; acrylic acid; 2,2'-azobisisobutyronitrile; heptane; aluminium acetylacetonate - norspan patches are indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. norspan patches are not indicated for use in chronic non-cancer pain other than in exceptional circumstances. norspan patches are not indicated as an as-needed (prn) analgesia.
norspan buprenorphine 5microgram/hour transdermal drug delivery system sachet
mundipharma pty ltd - buprenorphine, quantity: 5 mg - drug delivery system, transdermal - excipient ingredients: levulinic acid; oleyl oleate; povidone; polyethylene terephthalate; ethyl acetate; 2-ethylhexyl acrylate; vinyl acetate; butyl acrylate; acrylic acid; 2,2'-azobisisobutyronitrile; heptane; aluminium acetylacetonate - norspan patches are indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. norspan patches are not indicated for use in chronic non-cancer pain other than in exceptional circumstances. norspan patches are not indicated as an as-needed (prn) analgesia.
dutran 100 fentanyl 100 mcg/hr transdermal patch pouch
medis pharma pty ltd - fentanyl, quantity: 16.5 mg - drug delivery system, transdermal - excipient ingredients: titanium dioxide; polypropylene; polyethylene terephthalate; ethyl acetate; 2-ethylhexyl acrylate/2-hydroxyethyl acrylate/methyl acrylate copolymer; hexane - for the management of pain associated with cancer, palliative care, and other conditions in patients where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? severe enough to require daily, continuous, long term opioid treatment. not for use in opioid-na?ve patients.
dutran 75 fentanyl 75 mcg/hr transdermal patch pouch
medis pharma pty ltd - fentanyl, quantity: 12.375 mg - drug delivery system, transdermal - excipient ingredients: titanium dioxide; polypropylene; polyethylene terephthalate; ethyl acetate; 2-ethylhexyl acrylate/2-hydroxyethyl acrylate/methyl acrylate copolymer; hexane - for the management of pain associated with cancer, palliative care, and other conditions in patients where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? severe enough to require daily, continuous, long term opioid treatment. not for use in opioid-na?ve patients.
minitran 5 transdermal patches
viatris uk healthcare ltd - glyceryl trinitrate - transdermal patch - 5mg/24hour
transiderm-nitro 5 transdermal patches
novartis pharmaceuticals uk ltd - glyceryl trinitrate - transdermal patch - 5mg/24hour
nitro-dur 0.2mg/hour transdermal patches
organon pharma (uk) ltd - glyceryl trinitrate - transdermal patch - 5mg/24hour
minitran 10 transdermal patches
viatris uk healthcare ltd - glyceryl trinitrate - transdermal patch - 10mg/24hour